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Selenium compounds fall into two categories, organic and inorganic forms. The anticancer activity of selenium is dependent on its chemical form. In general, inorganic selenium compounds, such as selenate or selenite, are known to produce genotoxic effects, and are therefore not preferred for medicinal use especially at high doses. Organic selenium-containing compounds are better tolerated, but are different in their anticancer activity depending on their pharmacokinetic and pharmacodynamics properties. The metabolism of selenium to a monomethylated intermediate, methylselenol, is presumed necessary for the expression of anticancer activity [1] [2] [3] . Methylselenol is highly reactive and difficult to formulate. Stable precursors, such as methylselenocysteine or methylseleninic acid, or selenomethionine, which can be converted endogenously to methylselenol, are good selenium precursors for generating methylselenol, the active selenium metabolite that exhibit anticarcinogenic activity. Accumulating evidence suggests that organic selenium-containing compounds have better anticancer activity and are less toxic compared to inorganic selenium compounds. For these reasons, selenomethionine, presumably the major form of selenium in selenized yeast, is selected for the supplement used in SELECT trial. Despite the above advantage of organic selenium, inorganic selenium was also shown to have anticancer activity in prostate cancer [4] .
In our study, we tried to evaluate the in vitro and in vivo effect of inorganic selenium (sodium selenite) on tumor growth and food intake in ovarian carcinoma using animal model [5] . Because we used the partially immunodeficient (nude) mice in this study, the results of in vivo study could be different in immune competent models if selenium compound have some effects on immune system. Until now, there are a number of potential mechanisms proposed for the anti-proliferative effects of selenium, including antioxidant effects, enhancement of immune function, stimulation of apoptosis, and induction of cell-cycle arrest [6] . However, there are no conclusive evidences for which selenium compound including inorganic or organic forms is better and which route of administration is effective in treating cancer cells. Further experiments for pharmacokinetics and cytotoxic effect of various selenium compounds should be required to confirm this result.
